# Safety, Tolerability, and Pharmacokinetics of Switching From Oral Risperidone to Risperidone Implant

> **NCT04418466** · PHASE1,PHASE2 · COMPLETED · sponsor: **Delpor, Inc.** · enrollment: 34 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **COMBINATION_PRODUCT:** Risperidone

## Key facts

- **NCT ID:** NCT04418466
- **Lead sponsor:** Delpor, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-01
- **Primary completion:** 2023-02-10
- **Final completion:** 2023-02-10
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2024-12-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04418466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04418466, "Safety, Tolerability, and Pharmacokinetics of Switching From Oral Risperidone to Risperidone Implant". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04418466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*